Sort   by:  
 Page size 
UnknownNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Not available
S-EPMC5019749 | biostudies-literature
TranscriptomicsIntegrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
We integrate high-resolution copy number data with transcriptional profiles and identify the immunoregulatory genes, PD-L1 and PD-L2, as key targets at the 9p24.1 amplification peak in HL and MLBCL cell lines. DNA copy number alterations were defined in DLBCL and HL cell lines, normalized to healthy...
ORGANISM(S): Homo sapiens 
2010-10-06 | E-GEOD-22208 | biostudies-arrayexpress
UnknownNivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Not available
S-EPMC6075855 | biostudies-literature
UnknownMajor Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Not available
S-EPMC5877802 | biostudies-literature
TranscriptomicsGene Expression and HD-SNP6.0 data from Primary Testicular (PTL), Primary Central Nervous System Lymphoma (PCNSL) and Primary Mediastinal B-cell Lymphoma (PMLBCL)
We obtained gene expression data and HD-SNP6.0 copy number data from PTL, PCNSL and PMLBCL samples and performed an integrative analysis on them. RNA was whole genome amplified using Nugen. Gene expression profiles (GEP) and copy number (CN) data were obtained from 7 PTL. GEP was obtained from 15 PC...
ORGANISM(S): Homo sapiens 
2015-12-31 | E-GEOD-61578 | biostudies-arrayexpress
UnknownNivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Not available
S-EPMC5541855 | biostudies-literature
UnknownNivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Not available
S-EPMC10589773 | biostudies-literature
UnknownNivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Not available
S-EPMC11488644 | biostudies-literature
Sort   by:  
 Page size